Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the ...

Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

A new treatment for advanced melanoma is showing promising results for people whose tumors have stopped responding to ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Patients with skin cancer who were fed a high-fiber diet showed better response rates to treatment and longer event-free ...

Combining Scancell's melanoma drug iSCIB1+ with Yervoy and Opdivo significantly improved patient overall response rate.

Neoadjuvant immunotherapy is associated with high rates of event-free survival in patients with resectable melanoma.

WWE Hall of Famer Ric Flair is cancer free once again. Flair announced on Tuesday that he's completed his treatment for melanoma. Per TMZ, it was his second battle with skin cancer within the last ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...